2024
Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography
Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S, Motegi H, Toyonaga T, Hirata K, Fujimura M. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography. BioMed Research International 2024, 2024: 2973407. PMID: 38449509, PMCID: PMC10917478, DOI: 10.1155/2024/2973407.Peer-Reviewed Original ResearchConceptsPositron emission tomographyF-FDGMRNA expressionOverall survivalGlucose metabolismF-FDG positron emission tomographyAssociated with poor overall survivalProtein expressionEmission tomographyGross total resectionPotential key moleculesFluorine-18 fluorodeoxyglucoseHypoxic conditionsDegree of glucose metabolismMolecular mechanisms of glucose metabolismAggressive primary brain tumorPoor overall survivalPrimary brain tumorKey moleculesTotal resectionPreoperative examinationIntratumoral hypoxiaPrognostic valuePoor prognosisBiomarkers of glioblastoma
2023
Deep learning-based attenuation map generation with simultaneously reconstructed PET activity and attenuation and low-dose application
Shi L, Zhang J, Toyonaga T, Shao D, Onofrey J, Lu Y. Deep learning-based attenuation map generation with simultaneously reconstructed PET activity and attenuation and low-dose application. Physics In Medicine And Biology 2023, 68: 035014. PMID: 36584395, DOI: 10.1088/1361-6560/acaf49.Peer-Reviewed Original Research
2022
Deep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine
Toyonaga T, Shao D, Shi L, Zhang J, Revilla EM, Menard D, Ankrah J, Hirata K, Chen MK, Onofrey JA, Lu Y. Deep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 3086-3097. PMID: 35277742, PMCID: PMC10725742, DOI: 10.1007/s00259-022-05748-2.Peer-Reviewed Original ResearchConceptsNeural networkNovel deep learningNet neural networkPET/CT datasetsImage analysis metricsPhysics-based loss functionDeep learningCT-derived attenuation mapAttenuation mapLoss functionAnalysis metricsDetail recoveryTumor volume estimationMLAACT datasetsOSEM algorithmNetworkAlgorithmAttenuation correctionCorrection framework
2020
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study
Finnema SJ, Toyonaga T, Detyniecki K, Chen M, Dias M, Wang Q, Lin S, Naganawa M, Gallezot J, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study. Epilepsia 2020, 61: 2183-2193. PMID: 32944949, DOI: 10.1111/epi.16653.Peer-Reviewed Original ResearchConceptsMedial temporal lobe sclerosisTemporal lobe epilepsyTLE subjectsPositron emission tomographyLobe epilepsyJ BPSynaptic vesicle protein 2APartial volume correctionTemporal lobe sclerosisPositron emission tomography studyEmission tomography studiesSeizure onset zonePromising biomarker approachJ bindingPresurgical selectionSclerotic hippocampusHippocampal asymmetryTLE patientsRegional binding patternsControl subjectsCentrum semiovaleContralateral regionsEpilepsy patientsOutcome measuresOnset zone
2016
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, Terasaka S, Kobayashi H, Hattori N, Shiga T, Kuge Y, Tanaka S, Ito YM, Tamaki N. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 44: 611-619. PMID: 27752745, DOI: 10.1007/s00259-016-3541-z.Peer-Reviewed Original ResearchConceptsProgression-free survivalExtent of resectionStandardized uptake valuePositron emission tomographyGross tumor volumeFMISO positron emission tomographyMagnetic resonance imagingKarnofsky Performance ScaleOverall survivalTumor volumeGlioblastoma patientsHypoxia volumeFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyPotential prognostic factorsTotal lesion glycolysisMetabolic tumor volumeHypoxic volumeVolume of interestGadolinium-enhanced T1-weighted MR imagesReference regionT1-weighted MR imagesCytoreduction surgeryFree survivalPrognostic factors